Depleted Stem Cell Transplant ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
285	Fanconi anemia	2

285. Fanconi anemia

---

Clinical trials : 62 /  Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04784052 (ClinicalTrials.gov)	December 7, 2021	2/3/2021	Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing JSP191 Antibody	TCRaß+ T-cell/CD19+ B-cell Depleted Hematopoietic Grafts and a Reduced Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients With Fanconi Anemia	Fanconi Anemia	Drug: JSP191;Device: CliniMACS Prodigy System;Biological: Depleted Stem Cell Transplant;Biological: Rabbit Anti-Thymoglobulin (rATG);Drug: Cyclophosphamide;Drug: Fludarabine;Drug: Rituximab	Rajni Agarwal	NULL	Recruiting	2 Years	N/A	All	12	Phase 1/Phase 2	United States
2	NCT02065869 (ClinicalTrials.gov)	April 2014	13/2/2014	Safety Study of Gene Modified Donor T-cells Following TCRaß+ Depleted Stem Cell Transplant	Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRaß+ T Cells in Paediatric Patients Affected by Haematological Disorders	Acute Lymphoblastic Leukemia;Leukemia, Acute Myeloid (AML), Child;Lymphoma, Non-Hodgkin;Myelodysplastic Syndrome;Primary Immunodeficiency;Anemia, Aplastic;Osteopetrosis;Hemoglobinopathies;Cytopenia;Fanconi Anemia;Diamond Blackfan Anemia;Thalassemia;Anemia, Sickle Cell	Biological: BPX-501 T cells;Drug: Rimiducid	Bellicum Pharmaceuticals	NULL	Active, not recruiting	1 Month	18 Years	All	187	Phase 1/Phase 2	Italy;United Kingdom;Germany;Spain;United States